We are devoted to strengthening emerging pharmaceutical markets. To this end, we commit to upholding essential principles in all of our dealings with clients. Our Client Charter is our promise to you that ...
Our Quality Edge is how we blend Empathy, Reliability and Responsiveness to deliver exceptional service to all our clients.
We Partner with Clients to execute Outcomes Research in emerging markets.
We develop results-driven market access solutions for clients in emerging markets.
We are devoted to strengthening emerging pharmaceutical markets.
Market Access Solutions
Innovative Access Strategies
Our Quality Edge
United Kingdom Proposes Applying Price Controls to Biosimilars phrmaccess.com/x/qe pic.twitter.com/dlKQrzd0H4
About 13 hours ago from Carapinha & Company's Twitter
Americans Fund Most of the World’s Drug Research. Here’s How Trump Can End That phrmaccess.com/x/q9 pic.twitter.com/kJdWJxZdvp
About 15 hours ago from Carapinha & Company's Twitter
Drugs Not Working? Trump Administration Lets One State Pay Based on Effectiveness phrmaccess.com/x/q6 pic.twitter.com/SFODXvzIgJ
About 2 days ago from Carapinha & Company's Twitter
Drug prices not always aligned with value, researchers say: U.S. drug prices are not consistently linked to net health benefits phrmaccess.com/x/q7 pic.twitter.com/ZdFQRxrbov
The European Drug Pricing Dilemma Lurches Forwards phrmaccess.com/x/pw pic.twitter.com/ui3MH9uFNk
Last week from Carapinha & Company's Twitter
Switching to biosimilar and generic medicines saved the NHS over £300m in a year phrmaccess.com/x/px pic.twitter.com/mYhXRvtn4t
Roche Takes Drug-Price Posturing to New Heights phrmaccess.com/x/ox pic.twitter.com/wgursYG4qo
About 3 weeks ago from Carapinha & Company's Twitter